Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy

Kozo Ohkusu-Tsukada, Masahiro Toda, Heiichiro Udono, Yutaka Kawakami, Kimimasa Takahashi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cancer-induced immunotolerance mediated by inducible Treg (iTreg) is a major obstacle to cancer immunotherapy. In a basic study of immunotolerance, injection of an endogenous superantigen, i.e. the minor lymphocyte stimulatory (Mls)-1a, into specific TCR Vβ8.1-Tg mice enabled generation of anergic CD25- iTreg, the immunosuppressive function of which was maintained by IL-10 production via p38-MAPK activation. Interestingly, although p38-chemical inhibitor (p38-inhibitor) is capable of breaking CD25- iTreg-induced immunotolerance, the p38-inhibitor had hardly any immunotolerance breaking effect when CD25+ Treg were present, suggesting that depletion of CD25+ Treg is necessary for p38-inhibitor to be effective. Peptide OVA323-339 iv.-injection into its specific TCR-Tg (OT-II) mice also induced adaptive tolerance by iTreg. Peptide immunotherapy with p38-inhibitor after CD25+ Treg-depletion was performed in an OVA-expressing lymphoma E.G7-bearing tolerant model established by adoptive transfer of OT-II CD25- iTreg, which resulted in suppression of tumor growth. Similarly, the antitumor immunity induced by peptide immunotherapy in colon carcinoma CT26-bearingmice, in which the number of IL-10-secreting iTreg is increased, was augmented by treatment with p38-inhibitor after CD25 + Treg-depletion and resulted in inhibition of tumor progression. These results suggest that simultaneous inhibition of two distinct Treg-functions may be important to the success of cancer immunotherapy.

Original languageEnglish
Pages (from-to)1011-1021
Number of pages11
JournalEuropean Journal of Immunology
Volume40
Issue number4
DOIs
Publication statusPublished - 2010 Apr

Fingerprint

p38 Mitogen-Activated Protein Kinases
Interleukin-10
Immunotherapy
Neoplasms
Peptides
Superantigens
Injections
Adoptive Transfer
Immunosuppressive Agents
Immunity
Lymphoma
Colon
Lymphocytes
Carcinoma
Growth

Keywords

  • Anergy
  • Immunotherapy
  • Tolerance
  • Treg
  • Tumor immunology

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy. / Ohkusu-Tsukada, Kozo; Toda, Masahiro; Udono, Heiichiro; Kawakami, Yutaka; Takahashi, Kimimasa.

In: European Journal of Immunology, Vol. 40, No. 4, 04.2010, p. 1011-1021.

Research output: Contribution to journalArticle

Ohkusu-Tsukada, Kozo ; Toda, Masahiro ; Udono, Heiichiro ; Kawakami, Yutaka ; Takahashi, Kimimasa. / Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy. In: European Journal of Immunology. 2010 ; Vol. 40, No. 4. pp. 1011-1021.
@article{6bf83fb3d3644ff59ace031bd5f3d6c6,
title = "Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy",
abstract = "Cancer-induced immunotolerance mediated by inducible Treg (iTreg) is a major obstacle to cancer immunotherapy. In a basic study of immunotolerance, injection of an endogenous superantigen, i.e. the minor lymphocyte stimulatory (Mls)-1a, into specific TCR Vβ8.1-Tg mice enabled generation of anergic CD25- iTreg, the immunosuppressive function of which was maintained by IL-10 production via p38-MAPK activation. Interestingly, although p38-chemical inhibitor (p38-inhibitor) is capable of breaking CD25- iTreg-induced immunotolerance, the p38-inhibitor had hardly any immunotolerance breaking effect when CD25+ Treg were present, suggesting that depletion of CD25+ Treg is necessary for p38-inhibitor to be effective. Peptide OVA323-339 iv.-injection into its specific TCR-Tg (OT-II) mice also induced adaptive tolerance by iTreg. Peptide immunotherapy with p38-inhibitor after CD25+ Treg-depletion was performed in an OVA-expressing lymphoma E.G7-bearing tolerant model established by adoptive transfer of OT-II CD25- iTreg, which resulted in suppression of tumor growth. Similarly, the antitumor immunity induced by peptide immunotherapy in colon carcinoma CT26-bearingmice, in which the number of IL-10-secreting iTreg is increased, was augmented by treatment with p38-inhibitor after CD25 + Treg-depletion and resulted in inhibition of tumor progression. These results suggest that simultaneous inhibition of two distinct Treg-functions may be important to the success of cancer immunotherapy.",
keywords = "Anergy, Immunotherapy, Tolerance, Treg, Tumor immunology",
author = "Kozo Ohkusu-Tsukada and Masahiro Toda and Heiichiro Udono and Yutaka Kawakami and Kimimasa Takahashi",
year = "2010",
month = "4",
doi = "10.1002/eji.200939513",
language = "English",
volume = "40",
pages = "1011--1021",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy

AU - Ohkusu-Tsukada, Kozo

AU - Toda, Masahiro

AU - Udono, Heiichiro

AU - Kawakami, Yutaka

AU - Takahashi, Kimimasa

PY - 2010/4

Y1 - 2010/4

N2 - Cancer-induced immunotolerance mediated by inducible Treg (iTreg) is a major obstacle to cancer immunotherapy. In a basic study of immunotolerance, injection of an endogenous superantigen, i.e. the minor lymphocyte stimulatory (Mls)-1a, into specific TCR Vβ8.1-Tg mice enabled generation of anergic CD25- iTreg, the immunosuppressive function of which was maintained by IL-10 production via p38-MAPK activation. Interestingly, although p38-chemical inhibitor (p38-inhibitor) is capable of breaking CD25- iTreg-induced immunotolerance, the p38-inhibitor had hardly any immunotolerance breaking effect when CD25+ Treg were present, suggesting that depletion of CD25+ Treg is necessary for p38-inhibitor to be effective. Peptide OVA323-339 iv.-injection into its specific TCR-Tg (OT-II) mice also induced adaptive tolerance by iTreg. Peptide immunotherapy with p38-inhibitor after CD25+ Treg-depletion was performed in an OVA-expressing lymphoma E.G7-bearing tolerant model established by adoptive transfer of OT-II CD25- iTreg, which resulted in suppression of tumor growth. Similarly, the antitumor immunity induced by peptide immunotherapy in colon carcinoma CT26-bearingmice, in which the number of IL-10-secreting iTreg is increased, was augmented by treatment with p38-inhibitor after CD25 + Treg-depletion and resulted in inhibition of tumor progression. These results suggest that simultaneous inhibition of two distinct Treg-functions may be important to the success of cancer immunotherapy.

AB - Cancer-induced immunotolerance mediated by inducible Treg (iTreg) is a major obstacle to cancer immunotherapy. In a basic study of immunotolerance, injection of an endogenous superantigen, i.e. the minor lymphocyte stimulatory (Mls)-1a, into specific TCR Vβ8.1-Tg mice enabled generation of anergic CD25- iTreg, the immunosuppressive function of which was maintained by IL-10 production via p38-MAPK activation. Interestingly, although p38-chemical inhibitor (p38-inhibitor) is capable of breaking CD25- iTreg-induced immunotolerance, the p38-inhibitor had hardly any immunotolerance breaking effect when CD25+ Treg were present, suggesting that depletion of CD25+ Treg is necessary for p38-inhibitor to be effective. Peptide OVA323-339 iv.-injection into its specific TCR-Tg (OT-II) mice also induced adaptive tolerance by iTreg. Peptide immunotherapy with p38-inhibitor after CD25+ Treg-depletion was performed in an OVA-expressing lymphoma E.G7-bearing tolerant model established by adoptive transfer of OT-II CD25- iTreg, which resulted in suppression of tumor growth. Similarly, the antitumor immunity induced by peptide immunotherapy in colon carcinoma CT26-bearingmice, in which the number of IL-10-secreting iTreg is increased, was augmented by treatment with p38-inhibitor after CD25 + Treg-depletion and resulted in inhibition of tumor progression. These results suggest that simultaneous inhibition of two distinct Treg-functions may be important to the success of cancer immunotherapy.

KW - Anergy

KW - Immunotherapy

KW - Tolerance

KW - Treg

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=77951037826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951037826&partnerID=8YFLogxK

U2 - 10.1002/eji.200939513

DO - 10.1002/eji.200939513

M3 - Article

VL - 40

SP - 1011

EP - 1021

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 4

ER -